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ABSTRACT
Introduction: Prostate cancer (PC) is one of the most common cancers in the elderly population. The incidence 
is constantly growing. Radiotherapy for PC is rapidly evolving, which contributes to better cancer control. The 
escalation of RT dose requires better target localisation in order to avoid RT complications. Fiducial markers are 
improvements widely used for better accuracy of radiation.
Material and method: We implanted gold markers to 56 patients with confirmed PC between January and August 
2014. After the procedure we controlled complication rate and proper localisation of the markers. 
Results: No serious complication occurred. We observed a few cases of epididymitis, dysuria, and blood trace 
in urine. Four patients lost one seed. 
Conclusions: Implantation of fiducial markers is simple and save ambulatory procedure and improves the results 
of radical radiotherapy in PC due to exact positioning. 
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In Europe and United States prostate cancer is one 
of the most common male cancers [1]. The incidence 
in Poland in 2000 year was 8%. It was the third most 
common cancer in males after lung cancer (27%) and 
colon cancer (10%) [2]. Radical treatment options for 
local disease are radical prostatectomy or radiotherapy 
(brachytherapy or teletherapy). Current radiotherapy 
techniques compared to conventional 2DXRT are evo-
lving towards dose escalation and more precise planning. 
However, we know that incidence of complication after 
radiotherapy depends on dose and amount of irradia-
ted volume beyond the prostate margins. In order to 
improve the results of treatment new technologies, 
such as three-dimensional conformal radiotherapy (3D-
-CRT), intensity-modulated radiation therapy (IMRT) 
and volumetric modulated arc therapy (VMAT), were 
put to use worldwide in the last few years [3–5]. The 
procedures of treatment include applying many frac-
tions, so it is crucial to repeatedly deliver radiation to 
target. Image-guided radiation therapy (IGRT) uses 
real-time imaging to mould radiation beams to the tu-
mour. The linear accelerator delivers precise radiation 
dose different for the prostate, lymph nodes, seminal 
vesicles, and margins. Usually time of single irradiation 
in IMRT technique lasts 15–20 minutes. Using further 
refinement, such as RapidArc, improves dose confor-
mity with significant shortening of treatment time to 
5–7 minutes, so more patients can be irradiated during 
the day. RapidArc allows for changing simultaneously 
three parameters during treatment — rotation speed 
of gantry, shape of the treatment aperture using the 
movement of multi-leaf collimator leaves and delivery 
dose rate. Other way to further improve the radiotherapy 
results may be possible by better following inter-fractio-
nal movements of the treated organ. 
Prostate is not prone to large movements but it may 
shift slightly depending on respiration and rectum or 
bladder filling [6, 7]. Motions are predominantly in 
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the posteroanterior and cephalocaudal directions. Ho-
wever, as both organs — bladder and rectum — are 
located very close to prostate, they may easily get into 
the irradiation zone with danger of serious compli-
cations, even with the very small movements. Blad-
der and, especially, rectum wall are very vulnerable 
organs. External beam therapy produces rectal and 
genitourinary toxicities that can be early, which occur 
during or immediately after treatment, and late ap-
pearing after 6 months. The incidence differs much 
between the authors, but about 30% of patients present 
symptoms of acute proctitis or cystitis during therapy 
of prostate cancer. Other, usually late gastrointestinal 
symptoms are pain, bleeding, mucosal loss, higher 
stool frequency, ulceration, stricture, lymphedema 
and worse sphincter control [6]. Symptoms from geni-
tourinary system are dysuria, frequency, haematuria, 
severe nocturia, decreased stream and incontinence 
of urine. We observe that despite the treatment 5% 
to 10% of patients have permanent post-radiotherapy 
symptoms like irritable bowel, cystitis, intermittent 
rectal or bladder bleeding. 
Controlling the exact location of the prostate during 
subsequent sessions of image-guided external beam 
radiotherapy (IGRT) is an obvious method to improve 
precision and reproducibility of delivered doses [9, 10]. 
In order to achieve it, the utilization of fiducial markers 
has been proposed. The first use of gold markers for pro-
state localization was described by Crook and Raymond 
in 1995 in 56 patients treated with conventional telethe-
rapy 2DXRT [11]. These markers are also currently used 
with IMRT techniques. Use of 3 gold fiducials allows 
for reducing clinical target volume and planning target 
volume margins. The fiducials markers are effective 
method of localizing prostate displacement. The gold 
seed markers are radio-opaque and easily identified in 
x-ray, CT and MRI. They are also small and chemically 
inert in man. The implantation of fiducial markers is 
a simple procedure and is well tolerated by patients 
[12–14]. What is important, is that the markers must 
be positioned so they are forming 3D triangle. Implan-
tation can be performed by transperineal or transrectal 
way with ultrasound guide [15]. Usually, 3 seeds are 
implanted although in same centres 4 seeds were used. 
There are few types of seeds. They are pure gold cylin-
ders specially knurled to avoid migration; they differ in 
size and type of incisions. Seeds for soft tissue usually 
are 3 mm or 5mm long and 0.8; 0,9; 1,0; 1,2; 1,6 mm in 
diameter. Needle is 20 or 30 cm long and 18, 17 or 14 Ga 
of thickness. They are available in sterilized preloaded 
needles or alone [8]. 
Majority of articles describing the use of fiducial 
seeds are written by oncologist. In this article we would 
like to present urological aspect. Implantation is the 
simple and short procedure. In this study we present 
our experience in insertion of fiducial markers before 
radiotherapy of the prostate cancer
Material and method 
Between January 2014 and August 2014 we per-
formed 56 implantations by transrectal mode. All 
patients had confirmed prostate cancer on biopsy and 
were qualified for radical IMRT treatment. Diagnostic 
biopsies were performed in several local urological 
centres. Patients were qualified to set markers by a team 
of radiation oncologists. All 56 patients had cancer 
limited to the prostate. Mean age of the patients was 
69.5 years. Gleason grade ranged from 5 (in one case) 
to 10, mean 7. Gleason score 5 was recognized in 2003, 
but patient was submitted to the radiation only in 
2014. PSA level ranged from 1.99 ng/ml to 287 ng/ml. 
Seven patients had PSA between 46 and 287 ng/ml at 
the time of biopsy (287, 110, 91, 78, 66, 49, 46). These 
patients received neoadjuvant hormonotherapy after 
biopsy. Then they underwent CT of the abdomen and 
pelvis and a bone scan which excluded the spread of 
cancer. The patient with PSA 287 ng/ml in whom the 
diagnosis had been established in 2012, after 2 years of 
hormonotherapy was categorised to the radiotherapy at 
the PSA level 9.36 ng/ml. In CT and scintigraphy a guild 
of dissemination wasn’t found. All 55 patients had acinar 
carcinoma, but one patient had ductal carcinoma with 
PSA level 1.99 ng/ml. Mean PSA was 25.3 ng/ml. 
Technique
The used needle was 18 Ga, 20 cm long with cylindri-
cal marker 1 mm ¥ 3 mm (Riverpoint Medical Portland, 
Pre-Waxed Brachytherapy Needle). We inserted 1 seed 
in right lobe near apex, 1 in left lobe laterally in the mid-
dle of gland and 1 more in right lobe near bladder neck 
and urethra trying to create the tringle. Such a location 
was suggested by oncologists. 
Procedures were performed by 3 urologists. Before 
implantation patients received 2 doses of ciprofloxacin 
— 500 mg orally. We didn’t use bowel preparation. Du-
ring the procedure the patients were positioned on left 
lateral position. Only local anaesthesia with lignocaine 
gel was applied to the rectum few minutes before the 
procedure. The insertion was performed under TRUS 
control on simultaneous two cross-section picture. The 
needle was slowly inserted in the direction marked by 
the ultrasound tag and when the planned location has 
been reached the fiducial was released from the needle 
guide. Position correction was possible until the seed 
ejects from the needle. After implantation every patient 
underwent plain X-ray as a control of location of seeds 
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and usually 2–3 weeks later CT and MRI scan for plan-
ning EBRT. Patients have had radiotherapy conducted 
IMRT or RapidArc method.
Results
All 56 patients well tolerated the insertion. No 
complication occurred during procedure. No significant 
complications in the post-implantation period were 
seen. No urosepsis, gross haematuria, serious rectal 
bleeding or urinary retention were reported. No patient 
required hospitalization.
However small complications were observed. Two 
patients developed epididymitis which was treated 
with the antibiotic. The patients received ciprofloxacin 
for 10 days with a good clinical outcome. One patient 
had small rectal bleeding lasting 3 days. One patient 
complained of dysuria due to insertion of 1 seed into 
the wall of intraprostatic urethra. Complains passed 
after about 3 weeks. In CT scans 1 seed wasn’t found. 
The marker was probably expelled with urine, so after 
all the patient didn’t require additional treatment 
procedures. Some patients reported slight increase 
in urinary frequency, dysuria, and trace of blood in 
urine. These symptoms disappeared spontaneously 
within a few days and did not require special treatment. 
A total of four patients have lost one seed. Probably 
3 markers were excreted with stool and 1 with urine. 
The absence of seed was detected in control CT. The 
plausible explanation of this lost is that marker was 
implanted to the rectum wall. The patients who lost 
1 seed were irradiated according to the earlier esta-
blished schedule. We didn’t implant the fiducial seed 
in to replace the lost one, and no different technique 
of irradiation was used. No other complication during 
procedure occurred. 
Discussion
Implantation of radio-opaque markers to the prosta-
te gland helps in locating the gland during radiotherapy 
course [9–11]. Modern technology IGRT enables very 
precise planning of the dose. IMRT and VMAT allow 
dose escalation, but what is crucial for patient safety 
is a strict control of target position. The problem not 
completely solved even by the new modalities is how 
to secure the surrounding organs. The dose must be 
delivered to the same site during all subsequent frac-
tions. Therefore the key issues are exact positioning 
and adjusting the irradiation field to any movement of 
the treated organ. Movement of prostate is related to 
respiratory movement and to rectal and bladder filling. 
The movements are small (2–4 mm) and occur mainly in 
the anterior-posterior axis and superior-inferior axis, but 
because the organs are within very close proximity to the 
prostate, it creates the risk of side effects. Movement in 
lateral axis may be up to 1–2 mm [14, 16]. The benefit of 
higher doses is better cancer control, but disadvantage of 
this is higher toxicity to adjacent organs. All side effects 
of radiation significantly reduce the quality of life of 
patients even long time after completion of radiothe-
rapy. Treatment of side effects is difficult. Only grade 
2 toxicities which respond to simple management are 
reported between 26–35% [8]. Symptomatic treatment 
is long and very often ineffective. Symptoms tend to 
recur for many years. Serious complications from urinary 
and gastrointestinal system, such as faecal incontinence, 
rectal stricture or fistula, sometimes require urinary 
diversion and faecal stoma. The incidence of severe 
complications is decreasing despite of dose escalation 
due to the use of three-dimensional imaging systems. Fi-
ducial markers are simple method to accomplish precise 
maintenance of the treated field. The procedure is easy, 
similar to the transrectal biopsy [12, 15]. The idea of 
positioning the seeds is to create spatial block from 3 or 
4 seeds inserted inside prostate gland. Prostate motion 
known as inter-fractional motion occur between daily 
treatments and the other type intra-fractional motion 
occur during RT fraction. Radio-opaque marker and 
the use of electronic portal imaging give a direct eva-
luation of prostatic motion during radiation treatment. 
The CT scanner is part of the linear accelerator and 
determines the current location of the tumour and the 
prostate gland with submillimetre accuracy [9, 10, 14, 
16, 17]. Every day before treatment, location of gold 
seeds has been verified and compared with CT and MRI 
reference images. There is no need to implant seeds far 
from each other, because in such case some seeds are 
usually located in the rectal or urethra wall and are lost. 
The minimal space between markers should be 1 cm 
for better position verification. Other technical point 
is that the seed moves forward from applying needle 
and so the needle must be applied properly.. But the 
most important is the feed-back information from the 
radiotherapy team informing urologists how they can 
improve positioning. 
Conclusion
Implantation of fiducial markers to prostate is save 
and rather easy for urologists. In our group, we have 
seen that it helps in reducing the risk of irradiation of 
bladder and rectum and in this way prevents complica-
tions. The location of the prostate during radiotherapy 
is very accurate and precise. It is another example of 
the fact that close multidisciplinary cooperation brings 
a lot of merits to our patients. 
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Figure 1. Patient no 1. CT of pelvis in 3 dimensions and a 3-D reconstruction of the body with marked position of prostate. 
Fiducial seed in rectum wall — small arrow
Figure 2. Patient no 1 and his MRI of pelvis in 3 dimensions, three fiducial seeds appear as dark spots
Figure 3. CT of pelvis, two markers visible as bright spots. Big scrotal hernia marked by arrow
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Figure 4. CT scans, image for radiotherapy planning with markers. Calcification in prostate marked by arrow
Figure 5. MRI of pelvis before radiotherapy with markers
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